Replies to post #198795 on Biotech Values

[zipjet]

>>GILD—Simtuzumab phase-2 in IPF stopped for futility:

Was that considered a significant pipeline item of significant value to the stock price?

ij

[caravon]

GILD was never a good R&D house. They are a packaging/marketing giant.

[DewDiligence]

GILD discontinued Simtuzumab for NASH due to lack of efficacy, which is not surprising given the recent clinical failure (#msg-119622314).